IVZ vs TROW: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
TROW is the larger of the two ($22.01B market cap): the incumbent the market prices for continued execution (10.21x forward earnings, beta 1.45). IVZ is the smaller challenger ($11.77B), cheaper on forward earnings (8.09x): more room to run, but more to prove. On the numbers, IVZ leads on both counts: faster expected revenue growth (7% vs 1%) and a lower forward P/E (8.09x vs 10.21x). The case for TROW rests on its own driver (Active-to-passive flow pressure): if you believe in that, TROW fits; if you believe in what the numbers show today, IVZ does.
IVZ vs TROW: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | IVZ | TROW | What it tells you |
|---|---|---|---|
| Market cap | $11.77B | $22.01B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 8.09 | 10.21 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 1.65 | 1.45 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 42% of range | 49% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.16 | 1.94 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: IVZ is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how IVZ and TROW affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. IVZ and TROW share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined IVZ and TROW exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Invesco Ltd (IVZ) do?
Invesco Ltd. is a global independent investment management firm that manages money for retail and institutional clients across equities, fixed income, alternatives, and multi-asset strategies. It distributes through mutual funds, separately managed accounts, institutional mandates, and a large ETF business, and it is best known as the sponsor of Invesco QQQ, one of the largest and most heavily traded ETFs in the world. Because it earns fees on the assets it manages, Invesco's revenue moves with two things: the level of markets (which lifts or lowers asset values) and net client flows (money coming in or leaving).
What does T. Rowe Price Group (TROW) do?
T. Rowe Price Group is a Baltimore-based investment management firm and one of the largest active asset managers in the world, with assets under management around $1.71 trillion at the end of the first quarter of 2026. It manages money across mutual funds, exchange-traded funds, separately managed accounts, and retirement and target-date strategies, serving both individual investors and large institutions. Its business model is simple to understand: it charges fees as a percentage of the assets it manages, so revenue tracks two things closely, the market level of those assets and the net flow of client money in or out.
IVZ vs TROW: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- IVZ drivers: QQQ conversion unlocks new fees; Record AUM and durable inflows.
- TROW drivers: Active-to-passive flow pressure; ETFs, SMAs, and target-date growth.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant risk is market sensitivity: as a fee-on-assets business, Invesco's revenue and profits fall when equity and bond markets drop, so a sustained downturn would cut AUM and earnings quickly regardless of execution. For TROW, the dominant risk is the structural shift toward passive investing, which keeps pulling money out of active equity funds and pressures both fee rates and asset levels over time.
IVZ or TROW: which should you pick?
If the story you believe is IVZ's (QQQ conversion unlocks new fees), IVZ is the more direct way to own it; if it is TROW's (Active-to-passive flow pressure), TROW is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the IVZ and TROW guides.
IVZ vs TROW: the full fundamentals
IVZ. Figures are approximate and tied to the asOf date; verify live numbers before acting. At about $26.81 on November 20, 2026, Invesco trades near 8.1 times forward earnings and 1.2 times book with a yield near 3.1%, a lower multiple than in October after an 18% three-month decline, for an asset manager whose adjusted EPS is expected to grow about 37% in 2026; GAAP results show a trailing loss, so there is no meaningful trailing P/E. For an asset manager, AUM, flows, and fee rate matter more than a single quarter's EPS. The analyst mean target is about $35.13 across 15 analysts, and the next report is expected around January 26, 2027.
TROW. Figures are approximate and tied to the asOf date; verify live numbers before acting. At roughly 10 times earnings and a 5% yield, the market is pricing persistent outflows and flat earnings (consensus sees 2027 EPS of about $10.10, slightly below the ~$10.29 expected for 2026), so a cheap-looking valuation reflects real concern about shrinking active fund assets rather than an obvious bargain. A third-quarter beat on both revenue and EPS did little for the shares, which are roughly flat for the year as of November 20, 2026.
Headline figures (approximate, November 2026): IVZ shows revenue (ttm) ~$7.1 billion; latest quarter up ~14% YoY, adjusted eps (q3 2026) ~$0.72 vs ~$0.74 consensus, net income (ttm, gaap) ~-$316 million, operating margin (ttm) ~21% GAAP; TROW shows revenue (ttm) ~$7.70 billion; Q3 2026 revenue ~$2.01 billion, up ~6% year over year, net income (ttm) ~$2.13 billion, profit margin ~28%, operating margin ~34%, earnings per share Trailing ~$9.88; Q3 2026 EPS $2.86 vs ~$2.65 expected, p/e (trailing / forward) ~10.5x / ~10.2x.
The bottom line: IVZ vs TROW
IVZ and TROW are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined IVZ and TROW exposure against your real portfolio. It is not an investment adviser.
Wondering how IVZ or TROW fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Invesco Ltd
Ask Walnut's AI anything about IVZ and see how it fits what you own.
FAQ
What is the difference between IVZ and TROW?
+
Invesco Ltd. T. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is IVZ or TROW the better stock?
+
Neither is universally better. TROW is the larger incumbent; IVZ is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, IVZ or TROW?
+
On forward P/E (as of November 2026), IVZ trades at 8.09x and TROW at 10.21x, so IVZ is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both IVZ and TROW?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of IVZ vs TROW?
+
IVZ: The dominant risk is market sensitivity: as a fee-on-assets business, Invesco's revenue and profits fall when equity and bond markets drop, so a sustained downturn would cut AUM and earnings quickly regardless of execution. Fee compression is structural, with passive and ETF price wars (Invesco itself is cutting the QQQ fee) pressuring industry margins over time. Flows can reverse: eleven quarters of inflows can turn to outflows if performance lags or sentiment shifts. Heavy reliance on a single flagship product, QQQ, concentrates risk in the Nasdaq-100 and the tech-heavy names that drive it, and QQQ also faces new ETF competition. The private-markets push adds execution and partnership-dependency risk, and the firm carries debt and prior preferred obligations that constrain flexibility in a downturn. The QQQ upside is debated rather than assumed: in October 2026 analysts moved targets in both directions (Autonomous Research to $30 from $31, JPMorgan to $32 from $29.50), Q3 adjusted EPS then missed consensus by two cents, and the stock fell about 18% over three months to November 20 even as Mizuho initiated at outperform with a $37 target. TROW: The dominant risk is the structural shift toward passive investing, which keeps pulling money out of active equity funds and pressures both fee rates and asset levels over time. Fee compression is a related risk: as the industry competes on price, T. Rowe Price may have to lower fees to retain assets, squeezing margins even if flows stabilize. Because revenue is tied to market levels, a sustained equity or bond market decline would cut assets under management and earnings at the same time flows may be weakest, a double hit. Concentration in US growth strategies leaves it exposed if that style underperforms and clients rotate away. Finally, key-person and performance risk matters for an active manager: sustained underperformance by flagship funds can accelerate redemptions and damage the brand that justifies its fees. Analysts see little earnings growth ahead (2026 consensus EPS of about $10.29 and roughly $10.10 for 2027, a slight decline), Mizuho initiated coverage at Underperform with a $94 target on November 17, 2026, and the 14 analysts covering the stock lean to a hold rating with a mean target near $105, close to the current price, so the low multiple may persist without a change in flows.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell IVZ or TROW; figures are approximate and dated (as of November 2026). Verify current data before investing.